Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Other Non-Current Assets (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Other Non-Current Assets for 3 consecutive years, with $394000.0 as the latest value for Q3 2025.

  • Quarterly Other Non-Current Assets fell 9.84% to $394000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $394000.0 through Sep 2025, down 9.84% year-over-year, with the annual reading at $378000.0 for FY2024, 38.54% down from the prior year.
  • Other Non-Current Assets for Q3 2025 was $394000.0 at Mereo BioPharma, down from $402000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $615000.0 in Q4 2023, with the low at $378000.0 in Q4 2024.
  • Average Other Non-Current Assets over 3 years is $440142.9, with a median of $402000.0 recorded in 2025.
  • The sharpest move saw Other Non-Current Assets tumbled 38.54% in 2024, then decreased 9.84% in 2025.
  • Over 3 years, Other Non-Current Assets stood at $615000.0 in 2023, then crashed by 38.54% to $378000.0 in 2024, then increased by 4.23% to $394000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $394000.0, $402000.0, and $380000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.